JDJames E. Dahlman

James E. Dahlman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James E. Dahlman has a total of 254 co-authors. Here are the top co-authors by number of shared publications:

  • David Loughrey

    Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Emory University School of Medicine, Atlanta, USA

    23 shared publications
  • Kalina Paunovska

    Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA

    16 shared publications
  • Cory D. Sago

    Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA

    14 shared publications
  • Elisa Schrader Echeverri

    Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology

    13 shared publications
  • Melissa P. Lokugamage

    Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, USA

    13 shared publications
  • Philip J. Santangelo

    Wallace H. Coulter Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology

    12 shared publications

Latest Publications

  • Non-invasive nanoparticle barcoding in nonhuman primates

    by Bora Jang, Ryan Zenhausern, Liming Lian, Kara Gentry, Abdulraouf M. Abbas, Sebastian Rudden, Yoon-Joo Shin, Jessie Doan, David Loughrey, Elizabeth H. Curran, et al.


  • Open Access

    PAVR: High-Resolution Cellular Imaging via a Physics-Aware Volumetric Reconstruction Framework

    by Xuanwen Hua, Keyi Han, Zhi Ling, Olivia Reid, Zijun Gao, Hongmanlin Zhang, Edward A. Botchwey, Parvin Forghani, Wenhao Liu, Mithila Anil Sawant, et al.

    The rapid convergence of advanced microscopy and deep learning is transforming cell biology by enabling imaging systems in which optical encoding and computational inference are jointly optimized for volumetric information capture and interpretation. However, broadly accessible three-dimensional imaging at high spatiotemporal resolution remains constrained by volumetric reconstruction throughput, susceptibility to artifacts, and the burden of collecting modality-matched training data. Here, we introduce PAVR, a physics-aware light-field imaging platform that integrates single-shot volumetric acquisition with fast, end-to-end volumetric reconstruction. PAVR is trained entirely using in silico system responses, avoiding reliance on external high-resolution ground-truth modalities and enabling sample-independent reconstruction across diverse biological contexts. Using fixed and live mammalian cells, we demonstrate multicolor volumetric imaging of subcellular organelles, three-dimensional tracking of autofluorescent particles, and high-speed visualization of organelle remodeling and interactions. We further extend PAVR to quantify coupled morphological and functional dynamics in beating human induced pluripotent stem cell–derived cardiomyocytes under pharmacological perturbation. Together, PAVR establishes a scalable hardware–software platform for high-throughput volumetric imaging and quantitative analysis of dynamic cellular systems in both basic and translational settings.

  • Open Access

    High-throughput Genome Wide CRISPR Knock Out mechanical sort identifies genes driving metastatic cancer cell softening

    by Katherine M Young, Curtis N Dobrowolski, Nicholas Stone, Kalina Paunovska, Sydney Bules, Kelly Ahkee, James Hankish, Alex Chapman, James E Dahlman, Todd A Sulchek, et al.

    Cell mechanics can serve as an important biomarker for cell state and phenotype, such as metastatic ability. While some molecular mechanisms underlying cell mechanical properties have been investigated through targeted analyses, a genome-wide study of human genes and gene networks that modulate cell biophysical properties has not been attempted. In this work, we combined a microfluidic stiffness-based sorting device with a genome-scale CRISPR knockout (GeCKO) screen in order to investigate the effect of individual gene knockouts on cell stiffening and cell softening across the entire protein-coding genome. We processed approximately 150 million Cas9-expressing ovarian cancer cells that had been transduced with a library of 76,000 single guide RNAs (sgRNAs) against the 19,000 protein-coding genes in the genome. The cells were sorted into 5 mechanical subsets. We identified 7 gene knockouts that were significantly depleted in the softer subsets and over 700 gene knockouts that were significantly enriched in the stiffer subsets. Of these significant genes of interest, we selected 3 genes that were highly expressed in our ovarian cancer cell line with greater than 100-fold enrichment in the stiff outlet and resulted in significant changes in ovarian cancer patient survival. These genes, PIK3R4, CCDC88A, and GSK3B , when knocked out result in a significant and predicted increase in cell stiffness. This study is the first to explore the relation between human gene expression and cell mechanics at the genome-scale to generate datasets at the intersection between cell genotype, mechanotype, and phenotype for metastatic cancer cells. The method could also be applied to study the effect of genes on other biophysical cell processes as well as for identifying pathways for the control of cellular mechanics across many cell types.

  • Open Access

    Lipid nanoparticle GM-CSF replacement for autoimmune pulmonary alveolar proteinosis

    by Liming Lian, Bora Jang, Sebastian G. Huayamares, Avraham Shakked, Kara Gentry, Ryan Zenhausern, Afsane Radmand, Elisa Schrader Echeverri, Vaunita C. Parihar, Ricardo C. Guerrero-Ferreira, et al.

    Granulocyte–macrophage colony-stimulating factor (GM-CSF) deficiency drives autoimmune pulmonary alveolar proteinosis (aPAP), a disease characterized by impaired macrophage-mediated clearance of pulmonary surfactants. Clinical data suggest that inhaled recombinant GM-CSF reduces symptoms in aPAP patients, providing a rationale for mRNA-based GM-CSF replacement therapies. However, these require effective mRNA delivery after nebulization. Here, we report the iterative in vivo design of a lipid nanoparticle, named nebulized lung delivery 2 (NLD2), that efficiently delivers mRNA after nebulization. NLD2 carrying GM-CSF mRNA transfected alveolar macrophages in vivo, leading to interleukin-10 pathway activation and subsequent surfactant lipoprotein clearance. In a preclinical disease model of aPAP, GM-CSF mRNA delivery reduced surfactant protein thickness more than recombinant GM-CSF. These data support continued exploration of nebulized lipid nanoparticle therapies for aPAP.


  • Open Access

    Tumor agnostic drug delivery with dynamic nanohydrogels

    by Stephen N. Housley, Alisyn R. Bourque, Lilya V. Matyunina, Isabel A. Panicker, Elisa Schrader Echeverri, Marrissa Izykowicz, Olivia A. Herrmann, Sebinne Lee, Johana C. Arboleda, Vida Jamali, et al.

    RNA interference (RNAi) holds unique potential as a clinically viable modality to pharmacologically regulate oncogenes in sequence-specific manner. However, systemic delivery of RNAi to tumors encounters myriad obstructions, and strategies to overcome such barriers have largely consisted of academic demonstrations with few approaches reaching patients. Here we report the development of a self-agglomerating nanohydrogel (SANGs) platform that selectively localizes to tumor tissue, is efficiently internalized by cancer cells, is agnostic to RNAi payload, and achieves functional suppression of multiple oncogene targets. After intravenous injection, SANGs preferentially accumulate and are retained in primary and metastatic loci in four aggressive cancer models in rodents. SANGs deliver multiple RNAi payloads that significantly suppress oncogene expression and sensitize previously resistant tumors while being safe and well tolerated in simulated clinical applications across three species. We propose, and provide the first direct evidence in support of, a mechanism featuring emergent material properties by which SANGs achieve durable solid-tumor delivery without attachment of cell- or tumor-targeting ligands. Overall, the SANGs platform is an enabling technology for RNAi-based cancer therapeutics and is poised for advanced pharmaceutical development with multiple solid-tumor indications.


  • Open Access

    Glycolipid nanoparticles target the spleen and detarget the liver without charge

    by Kara Gentry, Liming Lian, Hyejin Kim, Ozgenur Celik, Camille Jones, Ananda R. Podilapu, Avraham Shakked, David Loughrey, Ryan Zenhausern, Bora Jang, et al.

    Lipid nanoparticles (LNPs) formulated with a neutral helper lipid can deliver RNA to the liver in humans. However, clinically relevant delivery to other tissues has remained challenging. To avoid the liver, scientists often add antibodies or helper lipids with a permanent charge. Here, we report an alternative approach: antibody- and charge-independent liver detargeting. Using DNA barcoding to test 109 chemically distinct LNPs in vivo, we found that replacing a neutral helper lipid with a neutral glycolipid reduced liver delivery and increased splenic delivery. Consistent with this differential tropism, these glycolipid nanoparticles caused differences in downstream cellular signaling in vivo compared to traditional LNPs. These data suggest that extrahepatic LNPs can be designed without the imposition of a net negative or positive charge.


  • Open Access

    Microfluidic Device Type Improves Heart mRNA Delivery In Vivo

    by Elisa Schrader Echeverri, Hyejin Kim, Bora Jang, Avraham Shakked, Christian Park, Kyung In Baek, Leandro Choi, Dong Won Kang, Ruei-Chun Hung, Kiyoung Jeong, et al.

    To improve lipid nanoparticle (LNP)-mediated delivery to nonliver tissues, scientists modify LNP chemistry or add targeting ligands. One underexplored alternative is to change the formulation process that creates the LNP. Here, we report that an LNP formulated with a herringbone mixer led to 2-fold more heart delivery than the same LNP formulated with a bifurcating mixer. The two LNPs had similar biophysical traits, yet they adsorbed different protein coronas, suggesting that the effect was driven by systemic physiology. By using spatial transcriptomics to track LNP delivery in a mouse model of atherosclerosis, we found that the improved LNP delivered mRNA to diseased regions and cardiomyocytes after an intravenous injection. These data suggest that it is possible to increase heart delivery via nanoparticle processing.


  • Open Access

    Gastrointestinal delivery of mRNA lipid nanoparticles selectively targets the pancreas

    by Abdulraouf M. Abbas, Ramy Ghanim, Sebastian Rudden, David Schultz, Avraham Shakked, Hyejin Kim, James E. Dahlman, Alex Abramson

    Lipid nanoparticles (LNPs) administered parenterally often show poor localization to the gastrointestinal (GI) tract and pancreas. In addition, patients typically prefer orally administered drugs to those given intravenously. We therefore investigated whether GI delivery, achievable via device mediated microneedle injections applied to buccal, gastric, small intestinal, colonic, or rectal tissues, could simultaneously enhance LNP delivery to the GI and pancreas while avoiding intravenous administration. Using a combined approach of formulation optimization and GI delivery site screening, we found that cationic SM-102 LNPs delivered gastrically achieved 7-fold higher pancreas delivery in rodents than intravenous neutral SM-102 LNPs. With dose optimization, gastric LNPs achieved 6000-fold greater pancreas to liver targeting ratios than intravenous LNPs. These results suggest GI microneedle administration can reprogram LNP biodistribution, thereby expanding therapeutic opportunities for both local and systemic nucleic acid delivery.


  • Open Access

    Development of a microneedle patch for delivery of mRNA-lipid nanoparticles

    by Sophia H. Sakers, B. Pradeep K. Reddy, Gianna Fiduccia, Katherine E. Byrne, Ingrid Stén, Julie Kim, Afsane Radmand, James E. Dahlman, Mark R. Prausnitz

    MRNA delivered by microneedle patch (MNP) can enable painless delivery, reduced need for healthcare expertise, and improved thermostability. In this study, we investigated formulation and manufacturing approaches for developing MNPs that deliver mRNA-loaded lipid nanoparticles (LNPs) encoding luciferase as a reporter protein during MNP fabrication and storage, including mRNA-LNP concentration, formulation, pH, excipients, and backing material. MNPs were assessed for mRNA-LNP size, encapsulation efficiency, and protein expression in vitro and in vivo. MNPs fabricated with mRNA-LNPs initially prepared at a higher concentration yielded superior expression compared to mRNA-LNP concentration by centrifugation or tangential flow filtration. Acidic pH during MNP manufacturing enabled greater expression in vitro. However, no such correlation was observed in vivo. Polyvinyl alcohol (PVA) best stabilized mRNA-LNPs during the MNP manufacturing process amongst the tested polymers. Incorporating sugars in MNPs did not further improve stability. Low temperature drying (5 °C) preserved mRNA functionality better compared to drying at 25 °C and 40 °C. Though there was significant activity loss initially (87% loss in 2 days at 40 °C), mRNA expression was stabilized for extended subsequent periods even at accelerated conditions (10% additional loss after 28 days at 40 °C). Our systematic approach identified key parameters for successful formulation and manufacturing approaches to incorporate mRNA-LNPs into MNPs, which could expand access to mRNA-based medical interventions.


  • Open Access

    Lipid nanoparticle screening in nonhuman primates with minimal loss of life

    by Ryan Zenhausern, Bora Jang, Elisa Schrader Echeverri, Kara Gentry, Randi Calkins, Elizabeth H. Curran, Jennifer S. Wood, Rachelle L. Stammen, David Loughrey, Prasanthi Chappa, et al.

    Understanding how well delivery in mice predicts delivery in nonhuman primates (NHPs) could make lipid nanoparticle (LNP) discovery more efficient. Yet, few LNP-mRNA drug candidates are tested in NHPs, in part because the experiments require more animals than is considered ethical. Here, to minimize animal use, we create a pool of sterile barcoded LNPs that are frozen, aliquoted and administered when an end-of-life NHP—an animal that is independently scheduled for euthanasia due to spontaneous disease—becomes available. We then administer this pool of 45 LNP-aVHH mRNAs with different chemistries intravenously to mice and NHPs and observe a higher amount of aVHH expression in NHPs than in mice. We characterize systemic physiological responses to LNP treatment using 47 clinically relevant variables and analyze the transcriptomic response alongside delivery in single cells from three tissues in vivo. These data suggest that multiple lipoprotein receptors may be associated with delivery. Altogether, end-of-life NHPs reduce animal use and may be informative preclinical models.